Get the Stockscreener App
10.94
3.36%
-0.38
After Hours:
10.75
-0.19
-1.74%
Fulcrum Therapeutics Inc stock is traded at $10.94, with a volume of 409.34K.
It is down -3.36% in the last 24 hours and up +9.40% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$11.32
Open:
$11.33
24h Volume:
409.34K
Relative Volume:
0.68
Market Cap:
$592.06M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-6.9241
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
-3.10%
1M Performance:
+9.40%
6M Performance:
+58.55%
1Y Performance:
+176.96%
1-Day Range:
$10.50
$11.46
1-Week Range:
$10.50
$12.05
52-Week Range:
$2.315
$12.19
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
10.94 | 612.62M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Jul-29-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-12-24 | Downgrade | Stifel | Buy → Hold |
| Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-25-23 | Initiated | Goldman | Neutral |
| Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-22-23 | Upgrade | Stifel | Hold → Buy |
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
How Fulcrum Therapeutics Inc. stock performs in stagflation2025 Dividend Review & AI Forecasted Entry and Exit Points - moha.gov.vn
Will Fulcrum Therapeutics Inc. stock benefit from AI adoptionSwing Trade & Stepwise Trade Signal Guides - moha.gov.vn
Contrasting Fulcrum Therapeutics (NASDAQ:FULC) and TG Therapeutics (NASDAQ:TGTX) - Defense World
Why Fulcrum Therapeutics Inc. stock is a must watch in 2025Weekly Stock Analysis & Real-Time Volume Trigger Notifications - moha.gov.vn
Fulcrum Therapeutics Inc (FULC) expanding its growth trajectory ahead - Setenews
Fulcrum Therapeutics (NASDAQ:FULC) Now Covered by Truist Financial - Defense World
Fulcrum Therapeutics stock price target raised to $18 from $12 at H.C. Wainwright - Investing.com Canada
Truist Securities Initiates Coverage of Fulcrum Therapeutics (FULC) with Buy Recommendation - Nasdaq
HC Wainwright & Co. Maintains Fulcrum Therapeutics (FULC) Buy Recommendation - Nasdaq
Truist Securities Initiates Buy Rating on Fulcrum Therapeutics (FULC) | FULC Stock News - GuruFocus
FULC Stock Boosted: HC Wainwright & Co. Raises Price Target to $ - GuruFocus
Truist Securities initiates coverage on Fulcrum Therapeutics stock with Buy rating - Investing.com UK
Insider Sell Alert: Robert Gould Sells 15,000 Shares of Fulcrum Therapeutics Inc (FULC) - GuruFocus
Fulcrum Therapeutics Director Sells 15,000 Shares - TradingView
[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dir Gould Sells 15,000 ($165.5K) Of Fulcrum Therapeutics Inc [FULC] - TradingView
Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC) and Arrowhead Pharmaceuticals (ARWR) - The Globe and Mail
Will Fulcrum Therapeutics Inc. stock deliver consistent dividends2025 Winners & Losers & Long-Term Growth Plans - newser.com
How Fulcrum Therapeutics Inc. stock valuations compare to rivals2025 Earnings Impact & Reliable Price Action Trade Plans - newser.com
Will Fulcrum Therapeutics Inc. stock gain from strong economyRate Hike & Low Risk Entry Point Tips - newser.com
What date does Fulcrum Therapeutics's (FULC) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
How Fulcrum Therapeutics Inc. stock compares to growth peersEarnings Recap Report & Real-Time Volume Triggers - newser.com
Fulcrum Therapeutics Inc. stock outlook for YEAR2025 Year in Review & Stock Portfolio Risk Control - newser.com
Is Fulcrum Therapeutics Inc. stock attractive for passive investorsJuly 2025 Fed Impact & Smart Investment Allocation Tips - newser.com
Will Fulcrum Therapeutics Inc. stock beat EPS estimatesQuarterly Earnings Report & Expert Approved Momentum Trade Ideas - newser.com
This Biotech Just Lost Half Its Value As Its Rival Celebrated - Investor's Business Daily
Identifying reversal signals in Fulcrum Therapeutics Inc.Weekly Market Report & Verified Stock Trade Ideas - newser.com
Momentum divergence signals in Fulcrum Therapeutics Inc. chartTrade Risk Assessment & Expert Approved Momentum Trade Ideas - newser.com
Multi asset correlation models including Fulcrum Therapeutics Inc.Quarterly Profit Summary & Consistent Growth Stock Picks - newser.com
Datanomix and Fulcrum Modernize Manufacturing Tech Stacks with Seamless ERP + Production Monitoring Integration - GlobeNewswire Inc.
How Fulcrum Therapeutics Inc. stock responds to policy changesQuarterly Performance Summary & Accurate Trade Setup Notifications - newser.com
Tick level data insight on Fulcrum Therapeutics Inc. volatilityBond Market & Daily Growth Stock Tips - newser.com
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):